Q: What is the role of probiotics in the treatment of acute clostridium difficile-associated diarrhea?

Cleveland Clinic Journal of Medicine

Volumn 76, Issue 7, 2009, Pages 391-392

  Miller, Kennon ^a   Fraser, Thomas ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

CLOSTRIDIUM DIFFICILE; DIARRHEA; DOSE RESPONSE; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; NOTE; PSEUDOMEMBRANOUS COLITIS; SACCHAROMYCES;

CLOSTRIDIUM DIFFICILE; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; PROBIOTICS; SACCHAROMYCES;

EID: 69749100622     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.76a.08112     Document Type: Note

References (12)

1. Dendukuri N, Costa V, McGregor M, Brophy JM. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ 2005; 173:167-170.
2. Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008; CD004611.
3. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101:812-822.
4. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271:1913-1918.
5. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000; 31:1012-1017.
6. Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999; 67:302-307.
7. Huff BA. Caveat emptor. "Probiotics" might not be what they seem. Can Fam Physician 2004; 50:583-587.
8. Coeuret V, Gueguen M, Vernoux J. Numbers and strains of lactobacilli in some probiotic products. Int J Food Microbiol 2004; 97:147-156.
9. Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005; 115;178-181.
10. Lherm T, Monet C, Nougière B, et al. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002; 28:797-801.
11. Salminen MK, Rautelin H, Tynkkynen S, et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis 2004; 38:62-69.
12. Merrigan MM, Sambol SP, Johnson S, Gerding DN. Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters. J Infect Dis 2003; 188:1922-1927.